中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2013年
13期
165-166
,共2页
ESBLs%肺炎克雷伯菌%大肠埃希菌%耐药性
ESBLs%肺炎剋雷伯菌%大腸埃希菌%耐藥性
ESBLs%폐염극뢰백균%대장애희균%내약성
extended-spectrum β-lactamases(ESBLs)%antimicrobial%Escherichia coli%Klebsiella pneumonia
目的了解本院产超广谱β-内酰胺酶(ESBLs)大肠埃希菌和肺炎克雷伯菌的耐药情况,为临床合理使用抗生素提供指导。方法收集2011年6月至2012年9月本院门诊及住院患者送检的各类细菌培养标本,采用VETEK-2全自动微生物鉴定药敏仪进行细菌鉴定及药敏检测。结果2011年6月至2012年9月本院门诊及住院患者分离出大肠埃希菌和肺炎克雷伯菌分别为361、365株,其中产ESBLs菌株分别为204株(56.5%)、69株(18.8%),产ESBLs菌株对亚胺培南、厄他培南、加替沙星全部敏感,对哌拉西林/他唑巴坦、阿米卡星敏感性较高,对其他B一内酰胺类抗菌药几乎全部耐药。结论医院及时监测产ESBLs菌的发生率及其耐药趋势以指导临床用药至关重要。
目的瞭解本院產超廣譜β-內酰胺酶(ESBLs)大腸埃希菌和肺炎剋雷伯菌的耐藥情況,為臨床閤理使用抗生素提供指導。方法收集2011年6月至2012年9月本院門診及住院患者送檢的各類細菌培養標本,採用VETEK-2全自動微生物鑒定藥敏儀進行細菌鑒定及藥敏檢測。結果2011年6月至2012年9月本院門診及住院患者分離齣大腸埃希菌和肺炎剋雷伯菌分彆為361、365株,其中產ESBLs菌株分彆為204株(56.5%)、69株(18.8%),產ESBLs菌株對亞胺培南、阨他培南、加替沙星全部敏感,對哌拉西林/他唑巴坦、阿米卡星敏感性較高,對其他B一內酰胺類抗菌藥幾乎全部耐藥。結論醫院及時鑑測產ESBLs菌的髮生率及其耐藥趨勢以指導臨床用藥至關重要。
목적료해본원산초엄보β-내선알매(ESBLs)대장애희균화폐염극뢰백균적내약정황,위림상합리사용항생소제공지도。방법수집2011년6월지2012년9월본원문진급주원환자송검적각류세균배양표본,채용VETEK-2전자동미생물감정약민의진행세균감정급약민검측。결과2011년6월지2012년9월본원문진급주원환자분리출대장애희균화폐염극뢰백균분별위361、365주,기중산ESBLs균주분별위204주(56.5%)、69주(18.8%),산ESBLs균주대아알배남、액타배남、가체사성전부민감,대고랍서림/타서파탄、아미잡성민감성교고,대기타B일내선알류항균약궤호전부내약。결론의원급시감측산ESBLs균적발생솔급기내약추세이지도림상용약지관중요。
Objective To investigate detection rate of two common strains of Enterobacteriaceae (Escherichia.coli and Klebsiella.pneumoniae) producing extended-spectrum β-lactamases(ESBLs) and to analyze their drug-resistance. Methods The VETEK-2 automicroscan sysmex was used to identify the pathogenic bacteria and conduct drug resistance test. Results The detection rates of ESBLs-producing E.coli were 204(56.5%) stains, The detection rates of ESBLs-producing K.Pneumoniae Were 69(18.8%) stains, The drug-resistant spectrum of Klebsiella.pneumoniae was similar to Escherichia.Coli.All tested strains , however, producing extended-spectrum β-lactamases(ESBLs) were sensitive to imipenew and meropenem. The resistance rates were low to Piperacillin-tazobactam , amikacin, and they could be used clinically. Conclusion Monitoring the incidence of ESBLs-producing strains and their drug-resistant trend is essential to guide clinical administration.